Table 2.
Baseline Clinical Characteristics of GeroCovid Vax study participants according to age group (n = 3004).
| Clinical characteristics | Total |
60–75 yrs |
76–85 yrs |
≥86 yrs |
p |
|---|---|---|---|---|---|
| (n = 3004) | (n = 626) | (n = 1000) | (n = 1378) | ||
| Age, mean (SD) | 83.1 (9.2) | 68.9 (4.6) | 81.3 (2.7) | 91.0 (3.6) | |
| M/F | 866/2138 | 314/312 | 285/715 | 267/1111 | 0.001 |
| Previous COVID-19 infection (n,%) | 833, 27.7 | 153, 24.4 | 271, 27.1 | 409, 29.7 | 0.001 |
| Seasonal Flu vaccine (n,%) | 1900, 63.2 | 403, 64.4 | 619, 61.9 | 878, 63.7 | 0.341 |
| Pneumococcal vaccine (n,%) | 783, 26.1 | 176, 28.1 | 257, 25.7 | 350, 25.4 | 0.010 |
| Number of comorbidities, *% | 0.012 | ||||
| 1–2 | 23.7 | 26.6 | 22.0 | 23.5 | |
| 3–4 | 32.6 | 36.8 | 33.0 | 30.3 | |
| ≥5 | 43.7 | 36.6 | 45.0 | 46.2 | |
| Mobility function* (n, %) | <0.001 | ||||
| Walk | 1140, 41.4 | 329, 55.7 | 399, 42.9 | 412, 33.3 | |
| Does not walk | 1210, 43.9 | 182, 30.8 | 379, 40.8 | 649, 52.5 | |
| Bedridden | 406, 14.7 | 80, 13.5 | 151, 16.3 | 175, 14.2 | |
| Frailty syndrome*, % | 18.80% | 11.80% | 19.50% | 21.70% | <0.001 |
(* = valid percent reported excluding missing variables).